1. Vascular normalization: a real benefit?

   • Domenico Ribatti

   Mini Review 03 June 2011 Pages: 275 - 278

2. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

   • Yu Sunakawa
   • Wataru Ichikawa
   • Yasutsuna Sasaki

   Original Article 19 October 2010 Pages: 279 - 284

   

3. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

   • Kyu-pyo Kim
   • Min-Hee Ryu
   • Yoon-Koo Kang

   Original Article 19 October 2010 Pages: 285 - 291

   

4. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

   • Matthew H. Kulke
   • Jennifer A. Chan
   • Charles S. Fuchs

   Original Article 20 October 2010 Pages: 293 - 300

   

5. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy

   • Kohei Shitara
   • Keitaro Matsuo
   • Kei Muro

   Original Article 20 October 2010 Pages: 301 - 307

   

6. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

   • Ahmet Bilici
   • Bala Basak Oven Ustaalioglu
   • Mahmut Gumus

   Original Article 22 October 2010 Pages: 309 - 316

   

7. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX

   • Myung Hee Chang
   • In Kyu Lee
   • Jae Ho Byun

   Original Article 24 October 2010 Pages: 317 - 323

   

8. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

   • Susan K. Peirce
   • Harry W. Findley
   • Donald L. Durden

   Original Article Open access 24 October 2010 Pages: 325 - 335

   

9. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

   • Maki Tanioka
   • Noriyuki Katsumata
   • Yasuhiro Fujiwara

   Original Article 26 October 2010 Pages: 337 - 342

   

10. Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles

    • Cui-Tao Lu
    • Ying-Zheng Zhao
    • Lu Zhang

    Original Article 27 October 2010 Pages: 343 - 348

    

11. Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization

    • Yee Soo Chae
    • Jong Gwang Kim
    • Hoyong Park

    Original Article 27 October 2010 Pages: 349 - 358

    

12. Conjugation of chlorin p ₆ to histamine enhances its cellular uptake and phototoxicity in oral cancer cells

    • Arpana Parihar
    • Alok Dube
    • P. K. Gupta

    Original Article 27 October 2010 Pages: 359 - 369

    

13. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

    • Yuan Yuan
    • Deirdre J. Cohen
    • Howard S. Hochster

    Original Article 27 October 2010 Pages: 371 - 378

14. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

    • Allyson J. Ocean
    • Paul Christos
    • Maureen E. Lane

    Original Article 28 October 2010 Pages: 379 - 388

    

15. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

    • Young-Soon Na
    • Kyung-Ah Jung
    • Tae Won Kim

    Original Article 03 November 2010 Pages: 389 - 398

    

16. Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias

    • William R. Waud
    • Karen S. Gilbert
    • John A. Secrist III

    Original Article 11 November 2010 Pages: 399 - 403

17. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

    • Yon Hui Kim
    • Amy Coon
    • Garth Powis

    Original Article 11 November 2010 Pages: 405 - 413

    

18. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

    • Athanasios Kotsakis
    • Sophia Agelaki
    • Vassilis Georgoulias

    Original Article 11 November 2010 Pages: 415 - 422

19. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

    • Robin L. Jones
    • David Olmos
    • Ian R. Judson

    Original Article 11 November 2010 Pages: 423 - 429

    

20. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations

    • Antonia Tsallas
    • John Jackson
    • Helen Burt

    Original Article 11 November 2010 Pages: 431 - 444

    

21. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice

    • Yasmine S. Touil
    • Johanne Seguin
    • Guy G. Chabot

    Original Article 11 November 2010 Pages: 445 - 455

    

22. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer

    • Eleni Andreopoulou
    • Thomas Chen
    • Franco Muggia

    Original Article 11 November 2010 Pages: 457 - 463

    

23. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling

    • Beom Soo Shin
    • Jürgen B. Bulitta
    • Sun Dong Yoo

    Original Article 11 November 2010 Pages: 465 - 475

    

24. Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells

    • Maria C. Messner
    • Myles C. Cabot

    Original Article 12 November 2010 Pages: 477 - 487

    

25. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells

    • Li-Yuan Bai
    • Hany A. Omar
    • Jing-Ru Weng

    Original Article 12 November 2010 Pages: 489 - 496

    

26. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice

    • Trung The Van
    • Masaki Hanibuchi
    • Saburo Sone

    Original Article Open access 16 November 2010 Pages: 497 - 504

    

27. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

    • M. Tanioka
    • H. Nokihara
    • T. Tamura

    Original Article 16 November 2010 Pages: 505 - 511

    

28. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

    • Lee Jia
    • Gregory S. Gorman
    • Craig W. Beattie

    Original Article 18 November 2010 Pages: 513 - 524

    

29. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

    • Muhittin A. Serdar
    • Erdim Sertoğlu
    • Murat Cihan

    Original Article 24 November 2010 Pages: 525 - 529

    

30. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

    • Jong-Mu Sun
    • Mi Hyun Nam
    • Myung-Ju Ahn

    Original Article 25 November 2010 Pages: 531 - 538

    

31. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

    • Ghassan K. Abou-Alfa
    • Stephan L. Chan
    • Chao-Jung Tsao

    Clinical Trial Report 19 May 2011 Pages: 539 - 545

32. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

    • Peter D. Boasberg
    • Charles H. Redfern
    • Alejandro D. Ricart

    Short Communication 24 April 2011 Pages: 547 - 552